Kepler upgrades Virbac to 'buy' on strong outlook

Virbac SA

31/10/2025 09:00

** Kepler Cheuvreux upgrades French animal health company Virbac VIRB.PA to "buy" from "hold", citing a stronger earnings outlook and receding execution risks

** The broker notes a broad-based recovery with growth reaccelerating across all regions while cost and currency pressures are easing, supporting the upgrade

** Kepler believes "visibility improving and operational volatility receding" offers renewed upside ahead of a more visible margin expansion in 2026

** Brokerage raises its FY25 EBIT margin forecast to 16.2%, supported by improved cost absorption and a resilient Companion Animals business mix

** Out of 9 analysts that cover Virbac, seven rate the stock "strong buy" or "buy," and ​two rate "hold" - LSEG data

 (Reporting by Hugo Lhomedet)

 ((Hugo.Lhomedet@thomsonreuters.com;))